
AIKI
Healthcare · Biotechnology & Medical Research · $19.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · -37.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 10, 2022 | After the close | -0.77 | -1.17 | -51.9% |
| Aug 12, 2022 | After the close | -0.68 | -1.18 | -73.5% |
| May 16, 2022 | Before the open | -0.34 | -1.19 | -250.0% |
| Mar 28, 2022 | After the close | -0.17 | -0.34 | -100.0% |
| Nov 10, 2021 | After the close | -0.51 | -0.00 | +99.9% |
| Aug 11, 2021 | After the close | — | -0.02 | — |
| May 10, 2021 | After the close | — | -0.07 | — |
| Mar 25, 2021 | After the close | — | 0.01 | — |
| Nov 13, 2020 | After the close | — | -0.06 | — |
| Aug 6, 2020 | After the close | — | -0.07 | — |
| May 14, 2020 | After the close | — | -0.91 | — |
| Mar 30, 2020 | After the close | — | 0.28 | — |
| Nov 12, 2019 | After the close | — | -1.38 | — |
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic…
| Aug 15, 2019 |
| After the close |
| — |
| -0.30 |
| — |
| May 15, 2019 | After the close | — | -2.43 | — |
| Mar 11, 2019 | After the close | — | 0.64 | — |
| Nov 14, 2018 | After the close | — | -0.22 | — |
| Aug 14, 2018 | After the close | — | -0.05 | — |
| May 15, 2018 | After the close | — | -0.23 | — |
| Mar 30, 2018 | After the close | — | -0.16 | — |